Key facts
- This page summarizes Sandra C. Patterson's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Mar 2025, 18:10.
Sandra C. Patterson - 10 Mar 2025 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- SVP, Controllership
- Issuer ticker
- GILD
- Reported as of
- 10 Mar 2025
- Net transaction value
- -$73,139
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 18:10:09 UTC
- Prior SEC filing
- 06 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward S. Son by Power of Attorney for Sandra C. Patterson
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sandra C. Patterson filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 06 Feb 2025.
- Current net transaction value: -$73,139.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GILD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,952
- Change %
- +5.1%
- Price
- Shares after
- 40,077
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
GILD
transaction
Common Stock
Tax liability
- Transaction value
- $73,139
- Shares
- -624
- Change %
- -1.6%
- Price
- $117.21
- Shares after
- 39,453
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -1,952
- Change %
- -17%
- Price
- Shares after
- 9,875
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,952
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Footnote F2
Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
Footnote F3
The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.